Last reviewed · How we verify
NCT07284602: SURPASS-IPF
A Randomized, Double-Blind, Head-to-Head Phase 3 Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone at 52 Weeks in Adults With Idiopathic Pulmonary Fibrosis (SURPASS-IPF)
Phase 3 trial testing Deupirfenidone in Idiopathic Pulmonary Fibrosis (IPF) in 1,100 participants. Not yet recruiting.
1 June 2029
Quick facts
| Lead sponsor | PureTech |
|---|---|
| Phase | Phase 3 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 1,100 |
| Start date | 1 April 2026 |
| Primary completion | 1 June 2029 |
| Estimated completion | 1 July 2029 |
Drugs / interventions tested
- Deupirfenidone — full drug profile →
- Pirfenidone (PFD) — full drug profile →
Conditions studied
- Idiopathic Pulmonary Fibrosis (IPF) — all drugs for Idiopathic Pulmonary Fibrosis (IPF) →
Sponsor
PureTech — full company profile →
Who can join
40 and older, any sex, with Idiopathic Pulmonary Fibrosis (IPF). Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Absolute change in forced vital capacity (FVC) measured in mL
Time frame: Baseline to Week 52
Evaluate the efficacy of deupirfenidone compared with pirfenidone on reduction in lung function decline in participants with IPF
Sponsor's own description
This is a study for adults with a lung disease called idiopathic pulmonary fibrosis. The main purpose of this study is to look at how well deupirfenidone improves lung function and how safe it is for people with idiopathic pulmonary fibrosis (IPF) when compared with pirfenidone. Participants may have been treated with an approved antifibrotic drug for up to a year in the past, but they cannot be on background antifibrotic treatment during this study. Participants will be randomly assigned (meaning by chance) to take either deupirfenidone or pirfenidone 3 times a day, and neither a participant nor their study team will know which study drug participants are on. Participants will be in the study for up to approximately 3 years. During the first year, participants visit the study site up to ten times and afterwards they visit the site every three months. All participants will remain on blinded study drug until the last participant has completed Week 52 Visit. They will have lung function tests, a check of their health, and will tell the study team about any unfavorable effects.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07284602
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Deupirfenidone
Trials testing the same drug.
- NCT05321420 — LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF) · Phase 2 · active not recruiting
- NCT07456800 — PK of Deupirfenidone Versus Pirfenidone in Older Healthy Subjects · Phase 1 · completed
Other recruiting trials for Idiopathic Pulmonary Fibrosis (IPF)
Currently open trials in the same condition.
- NCT07482917 — Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 Trial · NA · recruiting
- NCT07486206 — Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 Trial · NA · recruiting
- NCT06968845 — A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis · Phase 2 · recruiting
- NCT07466420 — Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases. · NA · recruiting
- NCT07464912 — A Adaptive Design Clinical Trial to Evaluate the Efficacy and Safety of TDI01 Suspension in the Treatment of Idiopathic · Phase 3 · recruiting
Other PureTech trials
Trials by the same sponsor.
- NCT06717100 — Study to Determine Potential for Drug-drug Interactions When Co-administering Deupirfenidone (LYT-100) and Nintedanib · Phase 1 · completed
- NCT05321420 — LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF) · Phase 2 · active not recruiting
- NCT05129865 — LYT-300 in Healthy Volunteers · Phase 1, PHASE2 · completed
- NCT07456800 — PK of Deupirfenidone Versus Pirfenidone in Older Healthy Subjects · Phase 1 · completed
- NCT04666688 — LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid · Phase 1, PHASE2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07284602 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by PureTech
- Last refreshed: 18 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07284602.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing